{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T17:08:20Z","timestamp":1782234500808,"version":"3.54.5"},"reference-count":31,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2010,6,14]],"date-time":"2010-06-14T00:00:00Z","timestamp":1276473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>A retrospective review and analysis of 275 patients with marginal zone lymphoma (MZL) was performed to determine prognostic factors. An effort was also made to establish a specific prognostic score for patients with extranodal MZL.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients were divided into 3 groups according to the type of MZL: extranodal, nodal, and splenic. Factors analyzed included age; gender; presence of B symptoms; Zubrod performance score; clinical stage; serum \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin, lactate dehydrogenase, albumin, and hemoglobin levels; and presence of autoimmune disorder.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>The 5\u2010year overall survival rates of patients with extranodal, nodal, and splenic MZL were 87%, 89%, and 93%, respectively (<jats:italic>P<\/jats:italic> = .95). On multivariate analysis, splenic MZL patients had the best prognosis (hazard ratio, 0.18; <jats:italic>P<\/jats:italic> = .018). An elevated serum \u03b2<jats:sub>2<\/jats:sub>\u2010microglobulin level (<jats:italic>P<\/jats:italic> = .010), B symptoms (<jats:italic>P<\/jats:italic> = .021), and male gender (<jats:italic>P<\/jats:italic> = .036) were found to be correlated with decreased recurrence\u2010free survival (RFS) on multivariate analysis. Using these 3 variables, a 3\u2010tier prognostic scoring system was created for patients with extranodal MZL: low\u2010risk with no adverse factors, intermediate\u2010risk with 1 adverse factor, and high\u2010risk with \u22652 adverse factors. The 5\u2010year RFS rates for the low\u2010risk, intermediate\u2010risk, and high\u2010risk groups were 80%, 71%, and 44%, respectively (<jats:italic>P<\/jats:italic> = .01).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Patients with extranodal and nodal MZL have a similar prognosis, whereas patients with splenic MZL have a better prognosis despite the increased prevalence of negative prognostic indicators. With the use of 3 readily available factors, a prognostic scoring system was identified for patients with extranodal MZL. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.25325","type":"journal-article","created":{"date-parts":[[2010,6,14]],"date-time":"2010-06-14T16:55:34Z","timestamp":1276534534000},"page":"4291-4298","source":"Crossref","is-referenced-by-count":43,"title":["Marginal zone lymphomas"],"prefix":"10.1002","volume":"116","author":[{"given":"Ali","family":"Mazloom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jeffrey","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter W.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando F.","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana L.","family":"Urbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bouthaina S.","family":"Dabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,14]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"214","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Isaacson PG","year":"2008"},{"key":"e_1_2_6_3_2","first-page":"218","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Campo E","year":"2008"},{"key":"e_1_2_6_4_2","first-page":"185","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Isaacson PG","year":"2008"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1409"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404517"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2405068"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01301.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4659"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)91723-H"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_6_12_2","volume-title":"World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue","author":"Jaffe ES","year":"2001"},{"key":"e_1_2_6_13_2","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4434"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm529"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1279"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2486"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06437.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0160-y"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00345.x"},{"key":"e_1_2_6_23_2","first-page":"80","article-title":"Marginal zone\u2010related neoplasms of splenic and nodal origin","volume":"88","author":"Arcaini L","year":"2003","journal-title":"Haematologica."},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04165.x"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.010"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20596"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.0723"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11835"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.3.802.003k19_802_806"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20874"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200306000-00006"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.2000.01108.x"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25325","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25325","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:24:29Z","timestamp":1760300669000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25325"}},"subtitle":["Factors that affect the final outcome"],"short-title":[],"issued":{"date-parts":[[2010,6,14]]},"references-count":31,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2010,9,15]]}},"alternative-id":["10.1002\/cncr.25325"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25325","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,14]]}}}